Four years ago, lured into a mainstream cardiovascular business by the promise of drug-eluting stents, Abbott set about revamping its medical products business in an effort to create a device business that would rival its pharmaceutical business in financial returns. What was at first a niche strategy, aimed at bringing small, but interesting technologies to interventionalists, has become a more broad-based play that, company officials hope, will place them among the leaders in vascular devices.
by David Cassak
For the most part, medical device companies like stealth—they like to move quickly and quietly beneath the radar screen of...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
